Keratosis pilaris‐like eruption secondary to nilotinib in a child

Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.